Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary
May 4, 2023
Earnings Call Speaker Segments
Ed Berg
executiveHello, everyone, and welcome to this afternoon's session. Representing Vaxart today are our Chief Executive Officer, Andrei Floroiu; Dr. Sean Tucker, who is our Founder and Chief Scientific Officer; Dr. James Cummings, our Chief Medical Officer; and Phillip Lee, our Chief Financial Officer. I'd like to note at the outset that during this call, Vaxart might issue forward-looking statements. These could cover the company's financial results, financial guidance, upcoming business strategies and operations, as well as progress in product development and regulatory matters — including statements regarding clinical trials that are underway or being planned. The figures we ultimately report may end up varying substantially from what these forward-looking statements describe, because several significant factors could come into play — among them the unpredictability that naturally surrounds drug development and the regulatory review pathway, plus the additional risks laid out under the Risk Factors heading in the 10-K annual report Vaxart filed most recently, along with its other periodic filings with the SEC. Vaxart assumes no duty to revise any forward-looking statements once this call has taken place. At this point I'll hand things over to Andrei Floroiu. Andrei?
Cezar Floroiu
executiveThanks, Ed, and I appreciate everyone being here today. During this call, our team is going to walk through the advances achieved this quarter in our oral pill vaccine effort targeting norovirus. We'll also go over where things stand with our oral pan-betacoronavirus vaccine plan and present data showing what makes our platform uniquely advantageous. Turning to norovirus first — the standout item this quarter was kicking off our Phase II dose-ranging trial for the bivalent oral norovirus vaccine candidate. We're still positioned to hit the milestones we laid out for 2023, with readouts expected later this year from the dose-ranging trial as well as from the ongoing Phase II challenge study of our G11 monovalent norovirus vaccine candidate. James is going to go deeper on those two studies shortly. Before that, though, a brief reminder about why this program and these trials matter so much for public health worldwide, and why we've committed ourselves to Vaxart's oral pill norovirus vaccine strategy. Norovirus represents a major public health problem, creating a substantial economic toll across developed nations, and no vaccine for it has been approved. Over 21 million individuals get infected annually in the U.S., producing a yearly disease burden exceeding $10 billion in the U.S. by itself. Worth noting: norovirus hits two groups hardest — kids younger than 5 and seniors. Roughly 20 million children live in the U.S., along with about 55 million older adults aged 65 and up. On top of that, around 15 million additional Americans could stand to gain from a norovirus vaccine, including health care and child care workers, which brings the overall domestic market opportunity to roughly 90 million Americans. Within the U.S., a lot of folks worry about Salmonella or E. coli. Yet when you count total cases, norovirus ranks as the most common foodborne illness by a wide margin. If you've kept up with the news, you're aware that anybody can catch norovirus — in schools, offices, and countless other settings where people crowd together in large numbers. Those who come down with norovirus symptoms end up missing school and work and can't carry out their everyday activities. We think our norovirus vaccine program could tackle this need and the enormous disease burden norovirus imposes, both across the U.S. and globally. So far, we've generated data from 6 finished norovirus clinical trials that together enrolled close to 350 subjects. Those results showed immune responses generated by our vaccine are potent and durable, matching what natural norovirus infection produces, and comparable between elderly and young adult groups — something injectable vaccines generally fail to achieve. In March, we highlighted our differentiated norovirus program on a virtual KOL call that we sponsored, featuring leaders in norovirus vaccine development; these experts offered their insights and views regarding the global <<inaudible>> effective and easily deployable norovirus vaccine. We trust a lot of you managed to take part in that educational session, since we keep working to inform the financial community about how big the unmet need is and what opportunity exists for a norovirus vaccine. You can find a replay of that session in the Investor Relations portion of our site, www.vaxart.com. Turning to what's ahead, we have a number of significant clinical milestones during this year, and we are still on schedule to reach them. To start, we anticipate sharing top line results from the Phase II dose-ranging trial of our bivalent norovirus vaccine candidate, which is ongoing, in mid-2023. After that, we expect to report top line data from the ongoing Phase II challenge study of our G11 monovalent norovirus vaccine candidate during the third quarter of this year; and following that, we are eager to launch this year the clinical trial funded by the Belen Melinda Gates Foundation, which will assess how well our norovirus vaccine candidate can induce antibodies in breast milk and pass those antibodies on to infants. Considered together, these milestones could help sustain the forward progress of Vaxart's norovirus program toward the Phase III trial, and they might also deliver additional validation of the potential of our norovirus pill vaccine platform. Norovirus has stayed relevant, both within the nation and around the world, and this chance to move our oral pill vaccine technology forward encourages us. At this point I'll hand the call over to James so he can review our norovirus program. James?
James Cummings
executiveThank you, Andrei. Our clinical team deserves real credit for the way they keep pushing our mission forward and driving meaningful progress with the Vaxart platform. In Q1 of this year, we dosed the first participant in the Phase II dose-ranging trial of our bivalent norovirus oral vaccine candidate. You'll remember that this candidate includes 2 key genotypes, G11 and G24, responsible for most human norovirus disease across the last 2 decades. As a reminder, 135 healthy adults were enrolled at 3 US sites in this trial. Open-label high-dose vaccine went to the first 10 sentinel subjects, while the rest were randomized among high-dose vaccine, low-dose vaccine, or placebo. There are 50 subjects in each of the vaccine arms, and 25 in the placebo arm. Safety and immunogenicity serve as the primary endpoints, which will let us set a dose level for Phase III development. Enrollment wrapped up in mid-April, and top line data from the study should be reported around the middle of this year. Should it succeed, a Phase IIb study comes next, which would lead to an end of Phase II meeting with the FDA during 2024. Back in March, we announced that we are expanding the number of cohorts in our ongoing Phase II G11 norovirus challenge study, which measures efficacy and safety for our monovalent norovirus vaccine candidate. This study is also built to identify a correlative protection linking immune responses to the vaccine with a lower risk of norovirus infection and/or acute gastroenteritis. Enrollment is now complete in this ongoing double-blinded study, and top line data is still expected in Q3 of 2023. In April, at the World Vaccine Congress in Washington, D.C., I presented on data from our norovirus program that had been previously disclosed. Those data show that our oral pill, bivalent norovirus vaccine candidate offers many broad advantages, among them the following: it generates broad immune responses through both mucosal and systemic pathways. For the high dose, immune response rates came in above 90%. Immune responses proved durable. They persisted beyond 200 days. Boosting of vaccine responses is possible after 1 year. Among the elderly, those aged 55 to 80 years in this study, immune responses looked very similar to those seen in younger adults aged 18 to 49. And last, the Vaxart coronavirus vaccine has a clean safety profile and has been well tolerated in this trial and in all of our clinical trials so far. Next week, 3 presentations will be given by us at the 8th International Calicivirus Conference in Rotterdam, the Netherlands. A paper on breast milk antibodies and the potential ability to block transmission will be presented by Dr. Sean Tucker, our Founder and CFO. Data showing that boost administration of our oral norovirus vaccine candidate at 18 months after bivalent immunization is effective in inducing potent immune responses will be presented by Dr. Becca Flutter. And to wrap up, I'll walk through a summary of what Vaxart has done so far with its bivalent vaccine, and I'll also share more specifics about our trials involving elderly participants. Our confidence in the promise of the bivalent norovirus candidate remains strong, since we're aiming for a BLA filing and a potential approval from the FDA; we're eager to bring you news on how things are going as we report developments from our Phase II clinical trials running at the same time. At this point I'll hand the call over to Dr. Sean Tucker, our Founder and Chief Science Officer, who will give an update on the pan-betacoronavirus program. Sean?
Sean Tucker
executiveAppreciate that, James. In terms of getting clinical and preclinical data out there and sharing it before key audiences of scientific and governmental leaders, our research team has advanced enormously. At the World Vaccine Congress this past month, I walked through data from Vaxart studies that had already been published, which showed how our vaccine platform can block transmission and give a boost to an existing COVID-19 vaccine. Our view is that the Vaxart COVID-19 vaccine carries an advantageous immune profile, hitting each of these targets: stability at room temperature; simplicity of administration; induction of serum antibody responses along with serum neutralizing antibody responses; generation of potent T cell responses; and production of a mucosal immune response. Transmission of the virus can be inhibited by it. It shows cross-reactivity toward SARS COV2 variants as well as other beta coronaviruses, and, crucially, it boosts the single most important COVID vaccine. Given everything we've reported so far on mucosal cross-reactivity from our clinical vaccine studies for COVID, we think there's a possibility we could develop an oral pan beta coronavirus vaccine; we keep working on new constructs that strengthen pan-betacoronavirus crosser activity, and once we're ready, our plan is to move those into the clinic. A vaccine of this kind would serve the dual purpose of guarding against viruses currently in circulation and future-proofing itself, whether against emerging coronavirus threats or other beta coronaviruses, which would make it a valuable asset for pandemic preparedness. To us, this approach makes an enormous amount of sense. Regulatory and governmental bodies keep showing interest in next-generation COVID-19 vaccines, and one sign of that is the Biden administration's reported proposal to commit as much as $5 billion toward such a next-generation coronavirus vaccine. With the aim of securing funding for our pan-betacoronavirus program, we're eager to keep engaging with the government. Now I'll hand the call to Phil for a quick run-through of the financials. Phil?
Phil Eric Lee
executiveThank you, Sean. Today's press release lays out the specifics of how we performed financially during the initial 3 months of 2023. As of the close of the first quarter of 2023, Factor held $71.8 million in cash, cash equivalents, restricted cash and marketable securities, down from $95.7 million on December 31, 2022. That reduction stemmed mainly from money spent on operations while we moved our norovirus program forward. Our view remains that the cash we have now gives us runway extending into the second quarter of 2024. All of us at Vaxart want to express our appreciation for the time you've given us today. At this point, we'll open up the call so you can ask your questions.
Mayank Mamtani
analystIt sounds like an mRNA player is now joining this norovirus vaccine push, which confirms both the burden of disease and the commercial opportunity you've described for some time, and you're clearly far ahead given that you're already in Phase II. Could you briefly walk through how the platforms differ and what advantages yours offers compared with, say, mRNA? Then I have one more question.
Sean Tucker
executiveSure. Let me share a bit — clearly, from the angle of eliciting antibody responses on mucosal surfaces, I believe our platform will perform very well, and norovirus certainly is a pathogen that attacks the intestinal stage. We're aware that we generate quite robust intestinal antibodies, so we believe that gives us an edge. mRNA vaccines, as you're aware, can perform quite well at generating serum antibody responses, yet those responses are typically somewhat more transient. From our data, at least with noroviruses, we're able to show serum antibodies persisting beyond 200 days. So I'd say we hold some meaningful advantages; and clearly, we're farther along.
Mayank Mamtani
analystGreat. Then regarding the monovalent Challenge study, could you comment on how the expected events when you designed the trial compare with where you stand now, and on anything else you've learned while running the study versus your initial plan? That would be great.
James Cummings
executiveLet me handle this one, Sean. James here. As you may remember, challenge studies generally are more aggressive than what occurs in nature, with no real-world disease occurrence. This study's sample size is designed mainly for descriptive statistical analysis, since our goal is really to understand how the vaccine works. For that, we have several measures under examination, including but not limited to a reduction in AGE acute gastroenteritis severity, a reduction in viral shedding, an impact on infectivity, and an impact on disease severity.
Jiale Song
analystGreat. A couple of fast questions on that. First, regarding the bivalent immunogenicity results expected around the middle of the year, could you tell us what you anticipate from those results, how the decision to proceed or not will be made, and — assuming a Phase IIb may be run — what designs might be used for it, given the Phase II immunogenicity findings you'll have at midyear? Yes, I have one more question after this.
James Cummings
executiveSure, Roger. James here. I'll give that a try. In the Phase II study, our 202-norovirus trial, we are evaluating safety along with immunogenicity for 2 separate dose levels of the bivalent construct; and we'll examine safety, which so far, knock on wood, looks well tolerated, just like our portfolio has historically. In addition, we'll assess immunogenicity and make a comparison between those 2 arms. I believe those are essentially the 2 elements we'll use in deciding which dose moves into the bigger Phase IIb study, allowing us to gather sufficient safety information for a subsequent discussion with the FDA following Phase II. That next study would probably require a few months. So if everything succeeds, we'd expect potentially 2024.
Jiale Song
analystUnderstood. So then, since you'll be getting the challenge study results for the monomer during the third quarter, while you're running the Phase IIb trial for the bivalent — do you anticipate doing a similar kind of change study prior to advancing into the pivotal stage? Or will you take the bivalent, along with the larger Phase IIb managing data, together with the monovalent challenge data, and proceed directly into the Phase III pivotal trial?
James Cummings
executiveWell, the way I see it, the order of things is that top line data from the 202 study — that's the Phase II dose comparison study, Part A — will come around midyear. And as we've mentioned during this conversation, top line results for the Challenge study should arrive in Q3 of this year. Those 2 data points matter quite a bit as we chart out what we do next. Does that address what you were asking, Roger? I'm not entirely certain I understood you correctly.
Jiale Song
analystGot it. I believe you already addressed this, though I'm still wondering — is an additional study needed for our bivalent before later-stage development can begin?
James Cummings
executiveThat's really something we'd need to discuss with the regulatory agencies once this data is available. Whether an extra study is required is a topic we'll be raising with the agency.
Ed Berg
executiveThanks. We received quite a few questions submitted online. James, the first one is directed at you. Over the past quarter, did you hold any further talks with the FDA? If you did, what was the context behind those talks, assuming there were any?
James Cummings
executiveAppreciate that, Ed. We hadn't scheduled any formal talks with the FDA during the quarter that just ended, and honestly, no such talks were necessary over that same period. That said, once the bigger Phase IIb studies wrap up, we do intend to hold a post-Phase II meeting with the FDA, which is what I told Roger.
Ed Berg
executiveEd also had a norovirus-related item, directed at Sean. He asked how crucial it is for the norovirus program overall to pin down a correlate of protection. Then he added a second question: what might those correlates reveal regarding the vaccine candidate and its likelihood of succeeding in Phase III?
Sean Tucker
executiveAppreciate that, Ed. Absolutely — grasping which immune measures actually track with success matters. It lets us move clinical development along faster. It gives you a sense of what to watch for during late-stage studies, and it clarifies that whatever adjustments you make to dose or to vaccination schedule may boost efficacy in a good way. Naturally, this isn't something you must have, though it's definitely a good thing to have, since it can accelerate your trials and clearly shrink the scale of your Phase III study.
Ed Berg
executiveAppreciate that, Sean. There's an additional question regarding the norovirus program. This one goes to James. If infants are vaccinated, could herd immunity play a part for norovirus — would adults end up protected as time goes on?
James Cummings
executiveYeah, that's a great question. We don't know how a vaccine would influence norovirus infectivity and transmission, since, as you're aware, no vaccine has been approved to date. That said, multiple studies give us insight here—they indicate that vaccinating young kids also leads to better health among adults. A fairly well-known study from Japan demonstrated that when young children received influenza vaccination, all cause mortality among elderly people dropped considerably. You may not be able to prevent every illness, but we do know kids pick up disease and then pass it along to their families, and that's one piece of global health we're hoping to tackle.
Ed Berg
executiveThere's another question coming in, and it's about the coronavirus — specifically our COVID program. Honestly, I think this one is for Sean and Andrei, if either of you wants to take it. So the question is this: The Washington Post did a story on the Biden administration's RFI regarding next-generation coronavirus vaccines, and in that piece, a possible $5 billion in funding was mentioned. Given that proposal from the Biden administration on next-gen vaccines, does it shift in any way the way you two are thinking about the pan-betacoronavirus program that came up earlier on this call?
Sean Tucker
executiveAbsolutely, and I appreciate you raising that. Once more, word of possible financial support for vaccines of the next generation represents encouraging movement. Our strategy, as I see it, isn't altered by what was announced, yet it likely mirrors what the broader scientific community agrees on — namely, that today's vaccine still has room for enhancement.
Cezar Floroiu
executiveRight, and to build on what Sean mentioned, the advancement we're seeing from the <<inaudible>> really validates the path we've taken. Anyone who has an RFI ready can back this up — the way the requirements are set and the emphasis on immunity aligns really well with what our platform offers. So these efforts give us a good amount of encouragement. And we're eager to find out how we might take part in it.
Ed Berg
executiveThanks, Andrei. Just one last thing. Sean, this is for you. Once more, about COVID. Is there a schedule you can share for getting a pan beta coronavirus vaccine candidate into the clinic?
Sean Tucker
executiveYeah, absolutely — we're still working on newer candidates, or I should say, research into constructs that we think could have greater potential for a strong Japan beta coronavirus vaccine; at this time we aren't giving any guidance. And once again, the timing hinges on a number of factors.
Ed Berg
executiveAll right. That wraps up the questions we received, so I'll hand things back to the operator.
Operator
operatorAll right, I appreciate it. That brings our call to a close. You're free to hang up at this point, and thanks once more for being with us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.